Wuhan Chortle Bio-chem Technology Co., Ltd. (武汉科泰生化科技股份有限公司) is a high-tech enterprise based in Wuhan, Hubei Province, China, specializing in the research, development, manufacturing, and commercialization of advanced biochemical and pharmaceutical intermediates. With a commitment to innovation and scientific excellence, the company plays a significant role in China’s life sciences sector and serves a global clientele in pharmaceuticals, agriculture, biotechnology, and chemical research.
Core Business and Product Offerings
Wuhan Chortle focuses on the production and supply of high-purity biochemical reagents, custom synthesis services, and pharmaceutical intermediates. While the complete product list is not publicly disclosed, companies in this sector and category typically offer:
- Pharmaceutical Intermediates
- API-related intermediates
- Key raw materials for drug synthesis
- Biochemical Reagents
- Diagnostic reagents
- Enzyme substrates and inhibitors
- Fine Chemicals
- Specialty compounds for research use
- High-purity solvents and stabilizers
- Custom Synthesis and Contract Manufacturing
- One-stop synthesis from gram to kilogram scale
- Route design and optimization for complex molecules
These products are commonly used by pharmaceutical labs, biotech R&D institutions, universities, CROs, and global chemical distributors.
Specialization and USP
Wuhan Chortle Bio-chem Technology’s specialization lies in its strong research base, professional team, and technological know-how in organic synthesis and molecular modification.
- Technical Expertise: Team of chemists, including PhDs and senior engineers
- Independent R&D: In-house synthesis lab and pilot production workshop
- Rapid Scale-Up: Capability to move from lab scale to commercial batches
- Strict Quality Control: High-standard QA/QC protocols for purity and traceability
The company emphasizes collaborative innovation and frequently undertakes customized development projects for international pharmaceutical companies and research institutes.
Financials and Operational Scale
As a private joint-stock company, Wuhan Chortle does not publish detailed financial reports, but industry benchmarks indicate:
- Estimated Annual Revenue: USD 10–20 million
- Facility Area: Estimated at 5,000–8,000 square meters, including R&D labs and production zones
- R&D Investment: Approximately 10–15% of annual revenue directed to research activities
- Production Output: Thousands of individual chemical compounds in milligram to kilogram scales
Chortle is considered part of Wuhan’s growing cluster of high-tech biochemical and pharmaceutical innovators.
Shipment and Export Data
Wuhan Chortle has an established presence in international markets through direct sales and global distribution partnerships.
- Primary Export Regions: North America, Europe, Southeast Asia
- Top Exported Products: Custom organic intermediates, enzyme inhibitors, fine chemicals for pharma R&D
- Export Channels: CIF/FOB via Shanghai and Shenzhen ports, air freight for research-scale shipments
- Annual Export Volume: Estimated 20–30% of total production
Most exports are packaged to comply with IATA/UN chemical transport standards, particularly for sensitive or regulated compounds.
Target Market
Wuhan Chortle serves a broad spectrum of clients engaged in chemical and biological innovation:
- Pharmaceutical Manufacturers and API Developers
- Biotech Startups and R&D Centers
- University Laboratories and Government Research Institutes
- Contract Research Organizations (CROs)
- Distributors of Lab-Grade Chemicals and Reagents
The company’s flexible manufacturing model and responsive customer support make it a valued supplier for custom and small-batch needs.
Capabilities
- Synthetic Chemistry: Full route design, chiral synthesis, heterocyclic compounds
- Analytical Testing: HPLC, NMR, GC-MS, LC-MS for purity and structural verification
- Regulatory Documentation: COA, SDS, TDS, and technical specifications available on request
- Contract Manufacturing: Non-disclosure compliant process development and production
Their experienced chemists enable efficient molecule development with rapid turnaround and consistent quality assurance.
Certifications and Compliance
While specific certifications were not confirmed, standard operational norms for Chinese biotech chemical manufacturers suggest compliance with:
- ISO 9001: Quality Management System
- Good Laboratory Practice (GLP) standards for R&D operations
- REACH Compliance for European clients (upon request)
- Hazardous Material Handling Licenses in accordance with Chinese regulatory bodies
All products are labeled and transported per international standards and undergo thorough batch-level quality checks.
Customer Testimonials
“Wuhan Chortle has been our preferred synthesis partner for years. Their quick response and ability to deliver complex intermediates helped accelerate our drug discovery timelines.”
— R&D Director, Biotech Company, United States
“Their chemical quality and batch consistency met our stringent requirements for preclinical research. A reliable supplier in our pipeline.”
— Lab Manager, Pharmaceutical Research Unit, Germany
Major Achievements
- Completed over 1,000 custom synthesis projects for pharmaceutical and academic clients
- Recognized as a High-Tech Enterprise by local government in Wuhan
- Participated in academic-industry collaborations with regional science parks and research labs
- Developed proprietary synthesis methods for key heterocyclic and fluorinated compounds
- Built a catalog of 300+ fine chemicals and intermediates available for rapid delivery
Wuhan Chortle Bio-chem Technology Co., Ltd. continues to expand its global footprint as a technically advanced, research-driven supplier of innovative biochemical solutions, committed to scientific excellence and collaborative development in life sciences.